文献速递MDS 与骨髓增殖性肿瘤白血病

体外药物筛选界定髓系肿瘤新型药物敏感性模式以指导个体化治疗

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.
PubMed 文献 · Blood Adv · 2020-01-01

研究评估全自动体外药物敏感性筛选平台,对54例初诊或难治性髓系肿瘤患者检测74种药物及36种组合的敏感性;在21例去甲基化药物难治患者的前瞻性可行性研究中,结果中位15天可获,阳性预测值0.92、阴性预测值0.82、总准确率0.85。

要点

  • 体外药物敏感性模式异质但可区分对去甲基化药物、蒽环类、组蛋白去乙酰化酶抑制剂和激酶抑制剂敏感性不同的患者集群(集群间P<.001)。
  • 去甲基化药物与维奈克拉联合在体外显示协同作用(联合 vs 单药P<.01)。
  • 在21例去甲基化药物难治患者中,体外筛选结果中位15天可获,阳性预测值0.92、阴性预测值0.82、总准确率0.85。

核心结论

  • 体外药物敏感性筛选平台可用于识别对标准治疗难治的髓系肿瘤患者潜在有用且常为新型的治疗药物。

研究设计与样本

  • 研究使用新型全自动高通量流式细胞术体外药物敏感性筛选平台,纳入54例初诊或治疗难治性髓系肿瘤患者,检测74种美国食品药品监督管理局批准或研究性药物及36种药物组合的敏感性(原始细胞细胞毒性和分化)。
  • 在33例患者中试运行平台后,开展前瞻性可行性研究纳入21例去甲基化药物难治患者,以确定该检测能否在临床可操作时间范围内完成并准确预测体内临床反应。

主要发现

  • 体外药物敏感性模式异质,但定义了對去甲基化药物、蒽环类、组蛋白去乙酰化酶抑制剂和激酶抑制剂敏感性不同的患者集群(集群间P<.001)。
  • 去甲基化药物与维奈克拉联合在体外显示协同作用(联合 vs 单药P<.01)。
  • 可行性研究中,体外药物敏感性筛选结果在骨髓活检后中位15天可获,并指导了个体化治疗,常包括维奈克拉联合方案、激酶抑制剂、分化剂和雄激素。
  • 在21例有体外和体内临床反应数据的患者中,该平台的阳性预测值为0.92,阴性预测值为0.82,总准确率为0.85。

关键数值与推荐

  • 患者集群间对去甲基化药物、蒽环类、组蛋白去乙酰化酶抑制剂和激酶抑制剂的敏感性差异P<.001。
  • 去甲基化药物与维奈克拉联合 vs 单药的协同作用P<.01。
  • 体外药物敏感性筛选平台阳性预测值0.92,阴性预测值0.82,总准确率0.85(21例有体外和体内临床反应数据的患者)。

临床怎么用

  • 作者认为该体外药物敏感性筛选方法可用于识别对标准治疗难治的髓系肿瘤患者潜在有用且常为新型的治疗药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that uses high-throughput flow cytometry in 54 patients with newly diagnosed or treatment-refractory myeloid neoplasms to evaluate sensitivity (blast cytotoxicity and differentiation) to 74 US Food and Drug Administration-approved or investigational drugs and 36 drug combinations. After piloting the platform in 33 patients, we conducted a prospective feasibility study enrolling 21 patients refractory to hypomethylating agents (HMAs) to determine whether this assay could be performed within a clinically actionable time frame and could accurately predict clinical responses in vivo. When assayed for cytotoxicity, ex vivo drug sensitivity patterns were heterogeneous, but they defined distinct patient clusters with differential sensitivity to HMAs, anthracyclines, histone deacetylase inhibitors, and kinase inhibitors (P < .001 among clusters) and demonstrated synergy between HMAs and venetoclax (P < .01 for combinations vs single agents). In our feasibility study, ex vivo DSS results were available at a median of 15 days after bone marrow biopsy, and they informed personalized therapy, which frequently included venetoclax combinations, kinase inhibitors, differentiative agents, and androgens. In 21 patients with available ex vivo and in vivo clinical response data, the DSS platform had a positive predictive value of 0.92, negative predictive value of 0.82, and overall accuracy of 0.85. These data demonstrate the utility of this approach for identifying potentially useful and often novel therapeutic drugs for patients with myeloid neoplasms refractory to standard therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Spinner MA, Aleshin A, Santaguida MT, et al. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Adv. 2020. PMID: 32569379. doi:10.1182/bloodadvances.2020001934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。